<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">AAPS PharmSciTech</journal-id><journal-id journal-id-type="iso-abbrev">AAPS PharmSciTech</journal-id><journal-title-group><journal-title>AAPS PharmSciTech</journal-title></journal-title-group><issn pub-type="epub">1530-9932</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31236781</article-id><article-id pub-id-type="pmc">6591193</article-id><article-id pub-id-type="publisher-id">1441</article-id><article-id pub-id-type="doi">10.1208/s12249-019-1441-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Liqui-Pellet: the Emerging Next-Generation Oral Dosage Form Which Stems from Liquisolid Concept in Combination with Pelletization Technology</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Lam</surname><given-names>Matthew</given-names></name><address><email>matthew.lam.researcher@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ghafourian</surname><given-names>Taravat</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Nokhodchi</surname><given-names>Ali</given-names></name><address><phone>+441273872811</phone><email>a.nokhodchi@sussex.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7590</institution-id><institution-id institution-id-type="GRID">grid.12082.39</institution-id><institution>Pharmaceutics Research Laboratory, Arundel Building, School of Life Sciences, </institution><institution>University of Sussex, </institution></institution-wrap>Brighton, UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7590</institution-id><institution-id institution-id-type="GRID">grid.12082.39</institution-id><institution>JMS Building, School of Life Sciences, </institution><institution>University of Sussex, </institution></institution-wrap>Brighton, UK </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2019</year></pub-date><volume>20</volume><issue>6</issue><elocation-id>231</elocation-id><history><date date-type="received"><day>7</day><month>2</month><year>2019</year></date><date date-type="accepted"><day>31</day><month>5</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">In spite of the major advantages that the liquisolid technology offers, particularly in tackling poor bioavailability of poorly water-soluble drugs (<italic>i.e.</italic>, BCS Class II drugs), there are a few critical drawbacks. The inability of a high liquid load factor, poor flowability, poor compactibility, and an inability to produce a high dose dosage form of a reasonable size for swallowing are major hurdles, hampering this technology from being commercially feasible. An attempt was therefore made to overcome these drawbacks whilst maintaining the liquisolid inherent advantages. This resulted in the emerging next generation of oral dosage forms called the liqui-pellet. All formulations were incorporated into capsules as the final product. Solubility studies of naproxen were conducted in different liquid vehicles, namely polyethylene glycol 200, propylene glycol, Tween 80, Labrafil, Labrasol, and Kolliphor EL. The scanning electron microscopy studies indicated that the liquid vehicle tends to reduce the surface roughness of the pellet. X-ray powder diffraction (XRPD) indicated no significant differences in the crystalline structure or amorphous content between the physical mixture and the liqui-pellet formulation. This was due to the presence of a high concentration of amorphous Avicel in the formulation which overshadowed the crystalline structure of naproxen in the physical mixtures. Flowability and dissolution tests confirmed that this next-generation oral dosage form has excellent flowability, whilst maintaining the typical liquisolid enhanced drug release performance in comparison to its physical mixture counterpart. The liqui-pellet also had a high liquid load factor of 1, where ~&#x02009;29% of the total mass was the liquid vehicle. This shows that a high liquid load factor can be achieved in a liqui-pellet without compromising flowability. Overall, the results showed that the poor flowability of a liquisolid formulation could be overcomed with the liqui-pellet, which is believed to be a major advancement into the commercial feasibility of the liquisolid concept.</p></abstract><kwd-group xml:lang="en"><title>KEY WORDS</title><kwd>liqui-pellet</kwd><kwd>liquisolid</kwd><kwd>dissolution enhancement</kwd><kwd>powder flow</kwd><kwd>naproxen</kwd><kwd>solid state analysis</kwd></kwd-group><funding-group><award-group><funding-source><institution>University of Sussex</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; American Association of Pharmaceutical Scientists 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>INTRODUCTION</title><p id="Par2">Liqui-pellet is an emerging novel oral dosage form, which improves the bioavailability of poorly water-soluble drugs <italic>via</italic> increasing drug release rate in the GIT. The poor drug dissolution rate of water-insoluble drugs is, in fact, a major issue confronting the pharmaceutical industry (<xref ref-type="bibr" rid="CR1">1</xref>). It is worth pointing out that around 60% of drugs in the market are poorly soluble in gastrointestinal fluids, which is based on biopharmaceutical classification system (BCS), and around 40% of drugs in development are identified as poorly water soluble (<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref>).</p><p id="Par3">Liqui-pellet stems from combining liquisolid concept with pelletization technology. It is fundamentally different from liquisolid technology in that it does not fit under the definition of liquisolid system; hence, it is called liqui-pellet instead of liquisolid pellet. Liquisolid formulation is described to be under liquisolid system, which refers to powdered form of liquid medication formulated by transforming liquid lipophilic drugs, or drug suspensions or solutions of water-insoluble drugs in an appropriate non-volatile liquid vehicle into dry looking nonadherent, free-flowing, and readily compressible powder admixtures by incorporating specific carriers and coating materials (<xref ref-type="bibr" rid="CR4">4</xref>). In this study, the liqui-pellet cannot be described as a liquisolid system because it is not necessarily in powder form and the admixture is not necessarily free-flowing, but rather a cohesive wet mass. The formulation only becomes free-flowing after becoming a pellet. In addition, the purpose of entitling the new dosage form as liqui-pellet is to emphasize the high liquid load factor or high amount of liquid vehicle it is capable of containing. This implies that a high amount of liquid medication can be incorporated into the formulation, which can result in either reduction in dosage weight or increased of API in solubilized state, or both. The new system is described as liqui-mass system, which is summarized in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. The liqui-mass system is versatile and different modifications can be applied to it. In this study, the key focus is producing liqui-pellet <italic>via</italic> liqui-mass system. However, it should be noted that this novel technology is still in its infancy; there is a high degree of flexibility for modification regarding liqui-pellet and the liqui-mass composition as shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Diagram summarizing the novel liqui-mass system which is used to make liqui-pellet</p></caption><graphic xlink:href="12249_2019_1441_Fig1_HTML" id="MO1"/></fig></p><p id="Par4">In order to have a good grasp of liqui-pellet, it is important to understand liquisolid technology. Liquisolid technology&#x02019;s simplistic approach and cost-effectiveness are desirable when considering manufacturing at a commercial scale (<xref ref-type="bibr" rid="CR5">5</xref>). In fact, the excipients used are conventional and commonly available in the market (<xref ref-type="bibr" rid="CR5">5</xref>). In addition to enhanced drug release, the formulation can be manipulated to achieve sustained drug release with a near zero-order release kinetic (<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref>). Despite the advantages, it has yet to overcome drawbacks, which hampers it from becoming a commercial product. This is mainly due to major issues such as poor flowability, poor compressibility, and the inability to produce high dose drug without being too bulky and heavy, which is not ideal for swallowing (<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR5">5</xref>). The flow property of the liquisolid blend is of critical importance in terms of manufacturing, particularly tablet or capsule form, as flow property determines uniform feed and reproducible filling (<xref ref-type="bibr" rid="CR8">8</xref>).</p><p id="Par5">In brief, the concept of liquisolid system is comprised of an active pharmaceutical ingredient (API), which is solubilized in a liquid vehicle, forming the liquid medication. This liquid medication is then incorporated into a carrier which is coated with nano-sized coating material to give the admixture of API and excipients a dry, free-flowing, and readily compressible properties (<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR9">9</xref>).</p><p id="Par6">Although there are other various technologies confronting the issue of poor drug dissolution rate of water-insoluble drugs, they may require advanced techniques, sophisticated machinery, and complicated technology or may not be cost-effective (<xref ref-type="bibr" rid="CR5">5</xref>). The other technologies include conversion of crystalline drug into its amorphous state (<xref ref-type="bibr" rid="CR10">10</xref>), micronization (<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>), solid dispersion (<xref ref-type="bibr" rid="CR15">15</xref>), co-grinding (<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>), nanosuspension (<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref>), self-emulsifying drug delivery system (<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref>), and inclusion of drug solution in soft gelatin capsule (<xref ref-type="bibr" rid="CR23">23</xref>). But in most cases, long-term stability is an issue. For example, on storage, highly amorphous materials can be converted to crystalline state which usually changes drug release profile (<xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref>).</p><p id="Par7">Since the focus of this study involves combining concept from liquisolid technology with pelletization technology, specifically extrusion-spheronization technology, the understanding of optimal extrudate properties for spheronization and parameters affecting the formation of pellets is prudent. In order to carry out wet extrusion, the material must display sufficient plastic property and cohesiveness to allow shaping and retention of the extrudate. The extrudate for pellet production should be self-lubricating and eventually brittle but not friable (<xref ref-type="bibr" rid="CR26">26</xref>). Moisture in the powder mass is one of the major factors necessary for providing plasticity for extrusion and spheronization, which have been subjected to much research (<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>). Water content is found to be one of the most important parameters (<xref ref-type="bibr" rid="CR31">31</xref>). Other factors that can affect pellets&#x02019; properties are water/granulating liquid temperature, extrusion speed, spheronization speed, and spheronization duration (<xref ref-type="bibr" rid="CR30">30</xref>).</p><p id="Par8">The aim of the present study is to make liqui-pellet, which has the inherent advantages from both liquisolid and pelletization technologies. The extrusion-spheronization technique can improve flow property, and the inherent advantages from the liquisolid aspect can enhance the drug release rate. The authors have termed this next-generation oral dosage form as liqui-pellet. This is to distinguish itself from the classical liquisolid compact, to emphasize the high liquid load factor it is capable of, and most importantly, to make clear that it is fundamentally different from liquisolid formulation in that it does not correspond to liquisolid system, but instead to liqui-mass system. The excellent flowability of liqui-pellet means there is more room to increase liquid load factor or the amount of liquid vehicle. The inherent advantages from pelletization technology include reduced risk of side effects due to dose dumping, combining incompatible drugs or drugs with different release profiles in the same dose unit (<xref ref-type="bibr" rid="CR33">33</xref>), and having good flow property (<xref ref-type="bibr" rid="CR34">34</xref>).</p></sec><sec id="Sec2"><title>MATERIALS AND METHODS</title><sec id="Sec3"><title>Materials</title><p id="Par9">Naproxen was obtained from Tokyo Chemical Industry Co (Japan). Other excipients used to prepare the liqui-pellet included microcrystalline cellulose (Avicel PH-101), (FMC Corp., UK); colloidal silicon dioxide (Aerosil 300), (Evonik Industries AG, Hanau, Germany); polyethylene glycol 200 (Fisher Scientific, Leicester, UK); propylene glycol (SAFC, Spain); polysorbate 80 (Tween 80), (Acros, Netherlands); linoleoyl macrogol-6 glycerides (Labrafil), (Gattefosse, Saint Priest, France); caprylocaproyl macrogol-8 glycerides (Labrasol), (Gattefosse, Saint Priest, France); and macrogolglycerol ricinoleate 35 (Kolliphor EL), (BASF SE, Ludwigshafen, Germany). All other reagents and solvent were of analytical grades.</p></sec><sec id="Sec4"><title>Solubility Studies</title><p id="Par10">Saturated solubility studies were carried out using 6 different liquid vehicles, <italic>i.e.</italic>, polyethylene glycol 200 (PEG 200), propylene glycol (PG), Tween 80, Labrafil, Labrasol, and Kolliphor EL (the liquid vehicles were selected on the basis of the published articles and their solubilizing effect on the drug (<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref>). The primary objective of using various mentioned liquid vehicles was to determine which liquid vehicle was the most suitable liquid vehicle for enhanced released naproxen liqui-pellet formulation. Saturated solutions were prepared by adding excess pure naproxen in a small vial containing 10&#x000a0;ml of specified liquid vehicle. The sample was then left in a bath shaker (OLS Aqua Pro, Grant Instruments Ltd., UK) for 48&#x000a0;h under a constant temperature of 37&#x000b0;C and shaking speed of 40&#x000a0;rpm. The supernatant was then filtered through a pre-heated filter (pore size 0.22&#x000a0;&#x003bc;m, Millex GP, Merck Millipore Ltd., Ireland), and diluted with phosphate buffer solution. This was then analyzed <italic>via</italic> a UV/vis spectrophotometer (Biowave II, Biochrom Ltd., UK) at wavelength 271&#x000a0;nm to determine the concentration of naproxen in each sample. Each test was carried out in triplicates.</p></sec><sec id="Sec5"><title>Preparation of Naproxen Liqui-Pellet</title><p id="Par11">The liqui-pellets were prepared by mixing pure naproxen in a chosen liquid vehicle (PEG 200, PG, Tween 80, Labrafil, Labrasol, and Kolliphor EL) using pestle and mortar method. All formulations contained Avicel PH-101 and Aerosil 300 as carrier and coating materials respectively, with a weight ratio of carrier to coating material of 20 (R-value). The liquid load factor for all liqui-pellet formulations was 1. Liquid load factor is the ratio of the weight of liquid medication over the weight of carrier excipient in the formulation admixture. Avicel PH-101 was mixed into the admixture to make sure the wet liquid medication was absorbed by the carrier and not leaving residual in the mortar when transferred into a mixer (Caleva Multitab, Caleva Process Solutions Ltd., UK). The sample was mixed for 10&#x000a0;min at a constant rate of 125&#x000a0;rpm with deionized water added bit by bit to achieve a desirable plasticity for extrusion (Caleva Multitab, Caleva Process Solutions Ltd., UK). The preliminary studies indicated that water content was a crucial factor to achieve extrudate with optimal plasticity for quality spherical pellet after spheronization (Caleva Multitab, Caleva Process Solutions Ltd., UK), which was further supported by the data published in the literature (<xref ref-type="bibr" rid="CR31">31</xref>). Aerosil 300 was then added into the admixture and further mixed for 10&#x000a0;min before the extrusion-spheronization process. Spheronization was set at an almost constant rotation at 4000&#x000a0;rpm (decrease to 3500&#x000a0;rpm if agglomeration seemed likely or increase to 4500&#x000a0;rpm to increase pellet sphericity); however, in each formulation, spheronization time varied depending on the extrudate plasticity property. Pellets were then placed in an oven under a constant temperature of 50&#x000b0;C overnight to remove water from pellets. Table <xref rid="Tab1" ref-type="table">I</xref> shows the details of each formulation with different liquid vehicles. Please note physical mixture pellet was prepared in the same manner as liqui-pellet except liquid vehicle was absent.<table-wrap id="Tab1"><label>Table I</label><caption><p>Key Formulation Characteristics of the Investigate Liqui-Pellet in Capsule</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Formulation</th><th>Liquid vehicle</th><th>Liquid vehicle concentration (% <italic>w</italic>/<italic>w</italic>)</th><th>Mass of carrier (mg)</th><th>Mass of coating material (mg)</th><th>Liquid load factor</th><th>Total weight of 25&#x000a0;mg naproxen liqui-pellet (mg)</th></tr></thead><tbody><tr><td>Physical mixture pellet</td><td/><td/><td>68.97</td><td>3.13</td><td/><td>90.63</td></tr><tr><td>LP-1</td><td>PEG 200</td><td>29.27</td><td>62.50</td><td>3.12</td><td>1</td><td>128.13</td></tr><tr><td>LP-2</td><td>PG</td><td>29.27</td><td>62.50</td><td>3.12</td><td>1</td><td>128.13</td></tr><tr><td>LP-3</td><td>Tween 80</td><td>29.27</td><td>62.50</td><td>3.12</td><td>1</td><td>128.13</td></tr><tr><td>LP-4</td><td>Labrafil</td><td>29.27</td><td>62.50</td><td>3.12</td><td>1</td><td>128.13</td></tr><tr><td>LP-5</td><td>Labrasol</td><td>29.27</td><td>62.50</td><td>3.12</td><td>1</td><td>128.13</td></tr><tr><td>LP-6</td><td>Kolliphor EL</td><td>29.27</td><td>62.50</td><td>3.12</td><td>1</td><td>128.13</td></tr></tbody></table><table-wrap-foot><p>Note, all formulation contains 25&#x000a0;mg of naproxen and the carrier to coating material is at a ratio of 20:1</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec6"><title>Evaluation of Naproxen Liqui-Pellet</title><sec id="Sec7"><title>Assay of Drug Content</title><p id="Par12">Assays were carried out in all naproxen liqui-pellet samples in order to confirm that all formulations contained the expected amount of drug that meets USP requirement of 90&#x02013;110%. Assays were carried out <italic>via</italic> crushing specified amount of pellets and dissolving the sample in a specified amount of phosphate buffer solution (pH 7.4) for spectrophotometric analysis (Biowave II, Biochrom Ltd., UK) at a wavelength of 271&#x000a0;nm where naproxen can be detected. The same method was used to test pure naproxen powder.</p></sec><sec id="Sec8"><title>Flowability Test on Liqui-Pellet</title><p id="Par13">Techniques of measuring flow property of the liqui-pellet that were used were flow rate in grams per second (Flowability tester, Copley Scientific, UK), angle of repose (Flowability tester, Copley Scientific, UK, and Digimatic height gauge, Mitutoyo, Japan), and Carr&#x02019;s compressibility index using the SVM tapped density tester (D-63150, Erweka, Germany). The flow rate was measured by recording the weight (g) and time (s) of pellets flowing through a 10-mm diameter orifice. The shutter was applied before funnel became empty of pellets. To determine the angle of repose, the pellets were placed in a funnel with a 10-mm diameter orifice and let the pellets flow onto a 100-mm diameter circular test platform. The digimatic height gauge and micrometer were used to measure the height and diameter of the heap of the sample, so that the angle of repose could be determined. Carr&#x02019;s compressibility index (CI%) was calculated from the poured (P<sub>b</sub>) and tapped (P<sub>t</sub>) densities using CI equation (Eq. <xref rid="Equ1" ref-type="">1</xref>). Tapped density was measured using the tapped density tester, which was set for 100 taps. All measurements were done in triplicates.</p><p id="Par14">
<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{CI}\%=\left({\mathrm{P}}_{\mathrm{t}}\hbox{--} {\mathrm{P}}_{\mathrm{b}}\right)/{\mathrm{P}}_{\mathrm{t}}\times 100 $$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mi>CI</mml:mi><mml:mo>%</mml:mo><mml:mo>=</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:msub><mml:mo>&#x02013;</mml:mo><mml:msub><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:msub><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:msub><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:math><graphic xlink:href="12249_2019_1441_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>
</p></sec><sec id="Sec9"><title>Friability Test on Liqui-Pellet</title><p id="Par15">Since there is no official standard for friability test on pellets, friability test was adapted using a similar method used by Hu <italic>et al</italic>. (<xref ref-type="bibr" rid="CR37">37</xref>). All formulations were tested. Pellets (3&#x000a0;g) and glass beads (3&#x000a0;g) were placed in a Erweka friabilator (D-63150, Erweka, Germany) under constant rotation of 25&#x000a0;rpm for 4&#x000a0;min. Note that the friabilator was sealed in order to prevent pellets leaving the container. Weight of the pellets before and after the friability test was recorded in order to calculate % weight loss.</p></sec><sec id="Sec10"><title>Particle Size Analysis <italic>via</italic> Sieve Method</title><p id="Par16">Sieves (Test sieve, Retsch, Germany) were used to determine the size distributions of all formulations. Pellets (5&#x000a0;g) were sieved under vibration <italic>via</italic> a mechanical shaker (AS 200, Retsch, Germany) for 1&#x000a0;min with an amplitude of 50, then a further 9&#x000a0;min with an amplitude of 40, using 2000, 1000, 850, 500, and 250&#x000a0;&#x003bc;m sieves. The pellets&#x02019; yield was determined based on the pellet fraction between 250 and 2000&#x000a0;&#x003bc;m and shown as the % of total pellet weight.</p></sec><sec id="Sec11"><title>Stereoscopic Analysis</title><p id="Par17">Stereoscopic analysis was performed on all formulations using an optical microscope (Nikon Labophot, Nikon, Japan), which was attached to a camera (Panasonic camera WVCL310, Panasonic, Japan). This allowed the mean Feret&#x02019;s diameter, roundness, and elongation ratio to be calculated using the particle size analysis software V1999 (designed in-house at King&#x02019;s College London). Note that 100 pellets per formulation were analyzed and the roundness and elongation ratio was calculated using Eqs. <xref rid="Equ2" ref-type="">2</xref> and <xref rid="Equ3" ref-type="">3</xref> respectively (<xref ref-type="bibr" rid="CR38">38</xref>).<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{Roundness}={\left(\mathrm{perimeter}\right)}^2/\left(4\times \uppi \times \mathrm{Area}\right) $$\end{document}</tex-math><mml:math id="M4" display="block"><mml:mtext>Roundness</mml:mtext><mml:mo>=</mml:mo><mml:msup><mml:mfenced close=")" open="("><mml:mtext>perimeter</mml:mtext></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>4</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mi mathvariant="normal">&#x003c0;</mml:mi><mml:mo>&#x000d7;</mml:mo><mml:mtext>Area</mml:mtext></mml:mrow></mml:mfenced></mml:math><graphic xlink:href="12249_2019_1441_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{Elongation}\ \mathrm{ratio}=\mathrm{Maximum}\ \mathrm{Feret}\ \mathrm{diameter}/\mathrm{Minimum}\ \mathrm{Feret}\ \mathrm{diameter} $$\end{document}</tex-math><mml:math id="M6" display="block"><mml:mtext>Elongation ratio</mml:mtext><mml:mo>=</mml:mo><mml:mtext>Maximum Feret diameter</mml:mtext><mml:mo>/</mml:mo><mml:mtext>Minimum Feret diameter</mml:mtext></mml:math><graphic xlink:href="12249_2019_1441_Article_Equ3.gif" position="anchor"/></alternatives></disp-formula></p></sec><sec id="Sec12"><title>Scanning Electron Microscope Analysis</title><p id="Par18">A scanning electron microscope (Jeol JMS 820, Freising, Germany) was used to observe the morphology of the pellets of each formulation. Each sample was placed in a double-sided carbon tape and sputter-coated with gold using a sputter coater (Edwards S-150 Sputter Coater, Edwards High Vacuum Co. International, USA) before placing in the scanning electron microscope (SEM) machine. The surface structure was then observed and recorded at magnifications of &#x000d7;&#x02009;80, &#x000d7;&#x02009;200, and &#x000d7;&#x02009;800, using the SEM which was operating at 3&#x000a0;kV.</p></sec></sec><sec id="Sec13"><title><italic>In vitro</italic> Drug Release Test</title><p id="Par19">All dissolution tests were carried out using USP paddle method (708-DS Dissolution Apparatus &#x00026; Cary 60 UV-Vis, Agilent Technologies, USA). The formulations in the form of liqui-pellets in capsules were under constant conditions of 900&#x000a0;ml of dissolution medium, paddle agitation of 50&#x000a0;rpm, and temperature of 37.3&#x02009;&#x000b1;&#x02009;0.5&#x000b0;C. Dissolution medium was either HCl buffer solution of pH 1.2 or phosphate buffer solution of pH 7.4 to simulate gastric fluid and intestinal fluid respectively without enzymes. Absorbance (at 271&#x000a0;nm) was taken at time intervals of 5&#x000a0;min until 1&#x000a0;h then time intervals of 10&#x000a0;min for another hour.</p><p id="Par20">All formulations contained 25&#x000a0;mg of naproxen. The reason for choosing 25&#x000a0;mg of naproxen was because of naproxen poor solubility profile at pH&#x000a0;1.2 due to its weak acidic properties. Naproxen would need to be able to dissolve completely at pH&#x000a0;1.2 in order for the dissolution test to be reliable. According to studies by Mora and Martinez (<xref ref-type="bibr" rid="CR39">39</xref>), naproxen solubility at 35&#x000b0;C and pH&#x000a0;1.2 was 1.16&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;4</sup>&#x000a0;mol/L or 27&#x000a0;mg/L, hence 25&#x000a0;mg used in test seemed reasonable. As for pH&#x000a0;7.4, naproxen was extremely soluble with a solubility of 1.455&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;2</sup>&#x000a0;mol/L or ~3347&#x000a0;mg/L. It should be noted that pH&#x000a0;1.2 sink condition was not maintained and this pH was only used for comparison of various formulations.</p></sec><sec id="Sec14"><title>Differential Scanning Calorimetry Studies</title><p id="Par21">Differential scanning calorimetry (DSC) (DCS 4000, Perkin Elmer, USA) was performed on the excipients, pure naproxen, and the chosen formulations with the fastest dissolution rate in order to assess their thermal behavior. Samples weighing between 3 and 6&#x000a0;mg were sealed in aluminum pan and thermal behavior was investigated at a scanning rate of 10&#x000b0;C/min, from 25to 200&#x000b0;C under nitrogen atmosphere.</p></sec><sec id="Sec15"><title>X-ray Powder Diffraction Studies</title><p id="Par22">X-ray powder diffraction (XRPD) was performed using an X-ray diffractometer (D5000, Siemens, Germany) on naproxen, excipients, and selected formulations to characterize the solid state of the materials used. Samples were scanned over a range of 2&#x003b8; at a voltage of 40&#x000a0;kV and current of 30&#x000a0;mA, with a scanning angle ranged from 5<sup>o</sup> to 40<sup>o</sup> and a scan rate of 0.2<sup>o</sup>/s.</p><p id="Par23">There were 2 methods of analyzing the % relative crystallinity, which were integrated peak method (Eq. <xref rid="Equ4" ref-type="">4</xref>) and peak height method (Eq. <xref rid="Equ5" ref-type="">5</xref>) (<xref ref-type="bibr" rid="CR40">40</xref>). For integrated peak method, the area under the peak was measured <italic>via</italic> the trapezoid method. In Eq. <xref rid="Equ4" ref-type="">4</xref>, A<sub>s</sub> is the integrated peak value of a sample and A<sub>r</sub> is the integrated peak value of a reference, which is usually the pure API. In Eq. <xref rid="Equ5" ref-type="">5</xref>, H<sub>s</sub> is the peak height value of a sample and H<sub>r</sub> is peak height value of a reference, which is usually the pure API.<disp-formula id="Equ4"><label>4</label><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \%\mathrm{XRD}\ \mathrm{relative}\ \mathrm{crystallinity}=\left({\mathrm{A}}_{\mathrm{s}}/{\mathrm{A}}_{\mathrm{r}}\right)\ \mathrm{x}\ 100 $$\end{document}</tex-math><mml:math id="M8" display="block"><mml:mo>%</mml:mo><mml:mi>XRD</mml:mi><mml:mspace width="0.25em"/><mml:mtext>relative crystallinity</mml:mtext><mml:mo>=</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">x</mml:mi><mml:mspace width="0.25em"/><mml:mn>100</mml:mn></mml:math><graphic xlink:href="12249_2019_1441_Article_Equ4.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ5"><label>5</label><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \%\mathrm{XRD}\ \mathrm{relative}\ \mathrm{crystallinity}=\left({\mathrm{H}}_{\mathrm{s}}/{\mathrm{H}}_{\mathrm{r}}\right)\ \mathrm{x}\ 100 $$\end{document}</tex-math><mml:math id="M10" display="block"><mml:mo>%</mml:mo><mml:mi>XRD</mml:mi><mml:mspace width="0.25em"/><mml:mtext>relative crystallinity</mml:mtext><mml:mo>=</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">x</mml:mi><mml:mspace width="0.25em"/><mml:mn>100</mml:mn></mml:math><graphic xlink:href="12249_2019_1441_Article_Equ5.gif" position="anchor"/></alternatives></disp-formula></p></sec><sec id="Sec16"><title>Statistical and Mathematical Analysis</title><p id="Par24">Mean cumulative % drug release after 2&#x000a0;h from the dissolution test were statistically analyzed by one-way analysis of variance (ANOVA). Results were quoted as significant where <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p><p id="Par25">Specific mathematical equations were used to analyze and compare dissolution profiles, which includes difference factor (f<sub>1,</sub> Eq. <xref rid="Equ6" ref-type="">6</xref>) and similarity factor (f<sub>2,</sub> Eq. <xref rid="Equ7" ref-type="">7</xref>) as described by Moore and Flanner (<xref ref-type="bibr" rid="CR41">41</xref>). Both methods have been recommended by the US FDA (Food and drug administration) (<xref ref-type="bibr" rid="CR42">42</xref>) and implemented by the FDA in various guidance documents (<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref>). In brief, f<sub>1</sub> value between 0 and 15 and f<sub>2</sub> value between 50 and 100 indicates equivalence of the two dissolution profiles (<xref ref-type="bibr" rid="CR45">45</xref>). Details of the equations can be found in various literature (<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR46">46</xref>&#x02013;<xref ref-type="bibr" rid="CR48">48</xref>). The <italic>n</italic> represents the number of dissolution sample times and <italic>R</italic><sub><italic>t</italic></sub> and <italic>T</italic><sub><italic>t</italic></sub> represent the mean % of drug dissolved at each time point (<italic>t</italic>).<disp-formula id="Equ6"><label>6</label><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {f}_1=\left\{\left[{\sum}_{t=1}\mathrm{n}|{R}_t-{T}_t|\right]/\left[{\sum}_{t=1}\mathrm{n}\;{R}_t\right]\right\}\bullet 100 $$\end{document}</tex-math><mml:math id="M12" display="block"><mml:msub><mml:mi>f</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mfenced close="}" open="{"><mml:mrow><mml:mfenced close="]" open="["><mml:mrow><mml:msub><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mi mathvariant="normal">n</mml:mi><mml:mo>|</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>|</mml:mo></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:mfenced close="]" open="["><mml:mrow><mml:msub><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mi mathvariant="normal">n</mml:mi><mml:mspace width="0.12em"/><mml:msub><mml:mi>R</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced><mml:mo>&#x02022;</mml:mo><mml:mn>100</mml:mn></mml:math><graphic xlink:href="12249_2019_1441_Article_Equ6.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ7"><label>7</label><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {f}_2=50\bullet \log \left\{{\left[1+\left(1/\mathrm{n}\right){\sum}_{t=1}\mathrm{n}\;{\left({R}_t-{T}_t\right)}^2\right]}^{-0.5}\bullet 100\right\} $$\end{document}</tex-math><mml:math id="M14" display="block"><mml:msub><mml:mi>f</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>50</mml:mn><mml:mo>&#x02022;</mml:mo><mml:mo>log</mml:mo><mml:mfenced close="}" open="{"><mml:mrow><mml:msup><mml:mfenced close="]" open="["><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mfenced><mml:msub><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mi mathvariant="normal">n</mml:mi><mml:mspace width="0.12em"/><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfenced><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:msup><mml:mo>&#x02022;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mfenced></mml:math><graphic xlink:href="12249_2019_1441_Article_Equ7.gif" position="anchor"/></alternatives></disp-formula></p></sec></sec><sec id="Sec17"><title>RESULTS AND DISCUSSION</title><sec id="Sec18"><title>Solubility Studies</title><p id="Par26">As shown in Table <xref rid="Tab2" ref-type="table">II</xref>, naproxen is most soluble in Kolliphor EL liquid vehicle and least soluble in Tween 80. Despite this, the formulation containing Tween 80 (LP-3) unexpectedly showed the fastest dissolution rate at pH 1.2 (this will be discussed later in the manuscript). It is generally thought that formulation containing the liquid vehicle with the highest solubility to the drug would exhibit the fastest drug release rate. This is due to less drugs in crystalline form and more drugs are in solubilized or in molecularly dispersed state in the carrier, thus increasing surface area for dissolution (<xref ref-type="bibr" rid="CR9">9</xref>).<table-wrap id="Tab2"><label>Table II</label><caption><p>Solubility of Naproxen in Various Liquid Vehicles at 37&#x000b0;C (<italic>n</italic>&#x02009;=&#x02009;3)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Non-volatile solvent</th><th>Mean concentration (mg/ml) &#x000b1; SD<sup>a</sup></th><th>Inference</th></tr></thead><tbody><tr><td>PEG 200</td><td>7.88&#x000a0;&#x000b1;&#x000a0;4.87</td><td>Slightly soluble</td></tr><tr><td>PG</td><td>5.13&#x000a0;&#x000b1;&#x000a0;0.78</td><td>Slightly soluble</td></tr><tr><td>Tween 80</td><td>2.99&#x000a0;&#x000b1;&#x000a0;1.01</td><td>Slightly soluble</td></tr><tr><td>Labrafil</td><td>10.73&#x000a0;&#x000b1;&#x000a0;1.15</td><td>Sparingly soluble</td></tr><tr><td>Labrasol</td><td>5.14&#x000a0;&#x000b1;&#x000a0;2.44</td><td>Slightly soluble</td></tr><tr><td>Kolliphor EL</td><td>15.83&#x000a0;&#x000b1;&#x000a0;0.77</td><td>Sparingly soluble</td></tr></tbody></table><table-wrap-foot><p>For the composition of each formulation, refer to Table <xref rid="Tab1" ref-type="table">I</xref></p><p><sup>a</sup>SD, standard deviation</p></table-wrap-foot></table-wrap></p><p id="Par27">It is noteworthy to point out that apart from drug solubility, other physicochemical characteristics of liquid vehicles such as lipophilicity, viscosity, polarity, chemical structure, and molecular mass may affect drug release behavior (<xref ref-type="bibr" rid="CR1">1</xref>). Hence, this may be the reason why the solubility result does not strictly match the drug release result. Nonetheless, the solubility of the drug in a liquid vehicle is a major factor that could greatly influence the drug release profile.</p></sec><sec id="Sec19"><title>Extrusion and Spheronization</title><p id="Par28">It should be noted that in the preliminary work, the moisture level or plastic property of extrudates greatly affects the success of spheronization. Extrudate plastic property is directly linked to the amount of water added, which is the granulating liquid. The more water added the greater degree of plasticity. When the extrudate&#x02019;s plasticity reaches above a critical point, it would usually be in a form of long threads rather than short threads (usually 3&#x02013;5&#x000a0;cm) as shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>. This extrudate&#x02019;s degree of plasticity was above the critical point, resulting in agglomeration during the spheronization as shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>. However, below the critical point, shorter extrudates are formed that successfully spheronized into pellets as shown in Fig. <xref rid="Fig2" ref-type="fig">2b, c</xref> and Fig. <xref rid="Fig3" ref-type="fig">3b, c</xref>. Thus, finding the optimal water content in extrudate has been seen prudent in making liqui-pellets. In addition, spheronization speed and time should be taken into account as high speed and long duration of spheronization could lead to agglomeration.<fig id="Fig2"><label>Fig. 2</label><caption><p>Image (<bold>a</bold>) of extrudate of a formulation (naproxen, Tween 80, Avicel, and Aerosil) containing high water content, exhibiting high plasticity. Image (<bold>b</bold>) of extrudate of a formulation (naproxen, PG, Avicel, and Aerosil) containing lower water content, exhibiting lower plasticity. Image (<bold>c</bold>) of extrudate of physical mixture formulation (naproxen, Avicel, and Aerosil)</p></caption><graphic xlink:href="12249_2019_1441_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Image (<bold>a</bold>) of agglomerated product after spheronizing a formulation (naproxen, Tween 80, Avicel, and Aerosil) containing high water content and longer threads. Image (<bold>b</bold>) of good quality pellets (spherical particles with less size variation) after spheronizing a formulation (naproxen, PG, Avicel, and Aerosil) containing lower water content and shorter threads. Image (<bold>c</bold>) of reasonable quality pellets (dumbbell shape would be considered less quality but reasonable) of physical mixture formulation (naproxen, Avicel, and Aerosil)</p></caption><graphic xlink:href="12249_2019_1441_Fig3_HTML" id="MO3"/></fig></p><p id="Par29">It can also be seen in Fig. <xref rid="Fig3" ref-type="fig">3</xref> that the quality of the pellets from formulation (b) can be similar or better than that of pellets without liquid vehicle (c). This could be due to liquid vehicle improving the rheological property of the extrudate to form good spherical pellets.</p></sec><sec id="Sec20"><title>Evaluation of Naproxen Liqui-Pellet</title><sec id="Sec21"><title>Liqui-Pellet Flow Property</title><p id="Par30">The results obtained from the flowability studies (Table <xref rid="Tab3" ref-type="table">III</xref>) indicate that liqui-pellet is indeed a very promising approach to overcome poor flowability with high liquid load factor, which is one of the biggest hurdles in current liquisolid technology. According to the angle of repose results (Table <xref rid="Tab3" ref-type="table">III</xref>), all formulations achieved excellent flow property apart from LP-3, which is in the borderline between excellent to good flow property. CI% results (Table <xref rid="Tab3" ref-type="table">III</xref>) show that all formulations achieved excellent flow property. Such results have never been achieved in liquisolid formulation with high liquid load factor before. Although there was an improvement in the flow of liqusolid powders by applying the granulation technique (<xref ref-type="bibr" rid="CR49">49</xref>), the liquid load factor was much lower than the liquid-pellet in the current study.<table-wrap id="Tab3"><label>Table III</label><caption><p>Flow Rate (g/s), Angle of Repose and Carr&#x02019;s Compressible Index (CI%) of All Liqui-Pellet Formulation (<italic>n</italic>&#x02009;=&#x02009;3)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Formulation<sup>a</sup></th><th>Flow rate (g/s) &#x000b1; SD<sup>b</sup></th><th>Angle of repose &#x000b1; SD<sup>b</sup></th><th>CI% &#x000b1; SD<sup>b</sup></th><th>Inference according to angle of repose</th><th>Inference according to CI%</th></tr></thead><tbody><tr><td>Physical mixture pellet</td><td>8.02&#x000a0;&#x000b1;&#x000a0;0.24</td><td>27.95&#x000a0;&#x000b1;&#x000a0;0.14</td><td>9.08&#x000a0;&#x000b1;&#x000a0;0.87</td><td>Excellent flow</td><td>Excellent flow</td></tr><tr><td>LP-1</td><td>8.85&#x000a0;&#x000b1;&#x000a0;0.16</td><td>25.89&#x000a0;&#x000b1;&#x000a0;0.95</td><td>6.07&#x000a0;&#x000b1;&#x000a0;1.71</td><td>Excellent flow</td><td>Excellent flow</td></tr><tr><td>LP-2</td><td>8.88&#x000a0;&#x000b1;&#x000a0;0.07</td><td>23.53&#x000a0;&#x000b1;&#x000a0;0.19</td><td>8.93&#x000a0;&#x000b1;&#x000a0;0.93</td><td>Excellent flow</td><td>Excellent flow</td></tr><tr><td>LP-3</td><td>5.67&#x000a0;&#x000b1;&#x000a0;0.28</td><td>30.26&#x000a0;&#x000b1;&#x000a0;0.09</td><td>3.38&#x000a0;&#x000b1;&#x000a0;0.71</td><td>Excellent-good flow property</td><td>Excellent flow property</td></tr><tr><td>LP-4</td><td>6.64&#x000a0;&#x000b1;&#x000a0;0.23</td><td>27.37&#x000a0;&#x000b1;&#x000a0;0.21</td><td>4.16&#x000a0;&#x000b1;&#x000a0;1.67</td><td>Excellent flow</td><td>Excellent flow</td></tr><tr><td>LP-5</td><td>7.10&#x000a0;&#x000b1;&#x000a0;0.16</td><td>27.52&#x000a0;&#x000b1;&#x000a0;0.24</td><td>3.18&#x000a0;&#x000b1;&#x000a0;1.58</td><td>Excellent flow</td><td>Excellent flow</td></tr><tr><td>LP-6</td><td>7.12&#x000a0;&#x000b1;&#x000a0;0.07</td><td>29.24&#x000a0;&#x000b1;&#x000a0;0.57</td><td>3.42&#x000a0;&#x000b1;&#x000a0;0.00</td><td>Excellent flow</td><td>Excellent flow</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>For the composition of each formulation, refer to Table <xref rid="Tab1" ref-type="table">I</xref></p><p><sup>b</sup>SD, standard deviation from the mean</p></table-wrap-foot></table-wrap></p><p id="Par31">It is interesting to see that the liquid load factor (L<sub>f</sub>) in liqui-pellet formulations is as high as 1 (Table <xref rid="Tab1" ref-type="table">I</xref>), which is considered very high in liquisolid formulations. In fact, 28% of the total mass of the pellets is co-solvent and yet the flow property is excellent. To put this into perspective, a comparison with various studies will be discussed. For example, in studies by Tiong and Elkordy, the naproxen liquisolid composition highest L<sub>f</sub> was 0.9 with very poor flow property (Carr&#x02019;s index of 31.58) (<xref ref-type="bibr" rid="CR35">35</xref>). Even the formulation with L<sub>f</sub> of 0.168 only had fair flow property (Carr&#x02019;s index of 20) (<xref ref-type="bibr" rid="CR35">35</xref>). In studies by Javadzadeh <italic>et al</italic>., it is claimed that with the use of an additive, such as PEG 3500, the L<sub>f</sub> can be increased (<xref ref-type="bibr" rid="CR36">36</xref>). They observed an increase of carbamazepine L<sub>f</sub> from 0.25 to 0.6, which is considered high (<xref ref-type="bibr" rid="CR36">36</xref>). It can be seen clearly that liqui-pellet L<sub>f</sub> is much higher than the formulations in the mentioned studies, and yet there are more rooms for liqui-pellet to be optimized such as incorporating polymeric additive. In studies by Hentzschel <italic>et al</italic>., a commonly used carrier (Avicel of specific grade) and coating material (Aerosil of specific grade) were replaced with Neusilin, which had a much larger specific surface area (SSA) than Avicel to make tocopherol acetate liquisolid tablet (<xref ref-type="bibr" rid="CR50">50</xref>). This large SSA increased the L<sub>f</sub> from 0.22 to 1.58 (factor of ~&#x02009;7); however, it was still limited by its flow property.</p><p id="Par32">With such high L<sub>f</sub> in liqui-pellet whilst still achieving excellent flow property, the implication for commercial use is very appealing as currently there is no liquisolid formulation in the market. Liquisolid technology in itself has great merits in the advantages it offers, but its drawbacks of poor flowability and larger mass of excipients in dosage form for high dose drug have made it difficult to establish itself for commercial use. In fact, with high L<sub>f</sub> and excellent flowability, it would seem possible that liqui-pellet can achieve acceptable weight for high dose drug since poor flow property is the key reason for bulky dosage form. Formulations with poor flowability due to liquid medication require more carrier and coating excipients to improve its flow property, thus increasing overall dosage form weight. The improvement of dosage form weight is currently undergoing studies by the authors. It would be fundamentally reasonable to postulate that liqui-pellet is highly commercially feasible without having the inherent advantages of liquisolid formulation compromised.</p><p id="Par33">It is also worth mentioning that due to flow property not being a major drawback in liqui-pellet, this effectively reduces the reliance on the current liquisolid mathematical model introduced by Spireas (<xref ref-type="bibr" rid="CR4">4</xref>). Flowable liquid-retention potential and compressible liquid-retention need less attention in liqui-pellet. In other words, high L<sub>f</sub> can be achieved whilst maintaining excellent flow property, and compressibility is not a major factor for pellets in capsules. Other parameters such as R-value and choices of excipients may not need to be compromised by flow property.</p><p id="Par34">Despite results obtained in this study, liqui-pellet and liqui-mass system are still in its infancy; there are still areas for further optimization in order to realize liqui-pellet full potential, which at present is undergoing studies by the authors.</p></sec><sec id="Sec22"><title>Determination of the Amount of API in Liqui-Pellet Formulation</title><p id="Par35">Assay <italic>via</italic> a spectrophotometer (Table <xref rid="Tab4" ref-type="table">IV</xref>) shows that all formulations except LP-2 have a good amount of drug nearing to 100%. What is unusual is that LP-2 shows ~&#x02009;30% more naproxen than expected. Initially, it is thought that this is due to experimental or processing error and so the LP-2 is remade but the assay still shows ~&#x02009;130% drug content. The absorbance of 25&#x000a0;mg naproxen in 900&#x000a0;mL of dissolution medium was increased from 0.47&#x02009;&#x000b1;&#x02009;0.01 to 0.63&#x02009;&#x000b1;&#x02009;0.02 when this dissolution medium contained an additional 40&#x000a0;mg PG (this was exactly how much PG associated with liqui-pellet formulation). The increase in the absorbance value in the presence of PG was calculated to be around 34%. This is in agreement with the dissolution data for LP-2 where the maximum dissolution percentage for LP-2 was around 130% which is 30% higher than expected. This indicates that the presence of PG interferes with the wavelength used to measure naproxen and this is the main reason for having more than 100% drug release (130%) for the samples containing PG. There have been other cases when PG interfers with absorbance reading such as in Dastidar and Sa studies (<xref ref-type="bibr" rid="CR51">51</xref>), where PG can interfere with the absorbance of diazepam causing an increase in the absorbance reading. It should be pointed out that since PG is not the chosen suitable liquid vehicle for naproxen liqui-pellet, there is no major issue concerning the interaction between naproxen and PG.<table-wrap id="Tab4"><label>Table IV</label><caption><p>Spectrophotometric Assay (Wavelength 271&#x000a0;nm) Showing % Drug Content in 25&#x000a0;mg Naproxen Formulations and Pure Naproxen Powder (<italic>n</italic>&#x02009;=&#x02009;3)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Formulation<sup>a</sup></th><th>Mean % drug release &#x000b1; SD<sup>b</sup></th></tr></thead><tbody><tr><td>Pure naproxen powder</td><td>98.78&#x000a0;&#x000b1;&#x000a0;0.23</td></tr><tr><td>Physical mixture pellet</td><td>96.54&#x000a0;&#x000b1;&#x000a0;2.30</td></tr><tr><td>LP-1</td><td>95.68&#x000a0;&#x000b1;&#x000a0;1.22</td></tr><tr><td>LP-2</td><td>129.68&#x000a0;&#x000b1;&#x000a0;0.58</td></tr><tr><td>LP-3</td><td>100.88&#x000a0;&#x000b1;&#x000a0;1.10</td></tr><tr><td>LP-4</td><td>101.84&#x000a0;&#x000b1;&#x000a0;0.66</td></tr><tr><td>LP-5</td><td>99.94&#x000a0;&#x000b1;&#x000a0;0.46</td></tr><tr><td>LP-6</td><td>101.79&#x000a0;&#x000b1;&#x000a0;1.27</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>For the composition of each formulation, refer to Table <xref rid="Tab1" ref-type="table">I</xref></p><p><sup>b</sup>SD, standard deviation from the mean</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec23"><title>Friability Test</title><p id="Par36">The results obtained from the friability test (Table <xref rid="Tab5" ref-type="table">V</xref>) show all formulations having % weight loss below 1%, which is considered acceptable for tablets under USP standard. This indicates that liqui-pellets are ideal for commercial manufacturing as it is robust to friability. The microcrystalline cellulose carrier forms strong bonding within its structure when water is added, producing pellets with a strong structure which is resistant to being friable. Also, the liquid vehicle in liqui-pellet increases the pellet plasticity, which effectively increases the pellet resistant to friability.<table-wrap id="Tab5"><label>Table V</label><caption><p>Weight Loss of 3&#x000a0;g of Each Formulation Under Rotational Speed of 25&#x000a0;rpm for 4&#x000a0;min</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Formulation</th><th>% weight loss</th></tr></thead><tbody><tr><td>Physical mixture pellet</td><td>0.54</td></tr><tr><td>LP-1</td><td>0.03</td></tr><tr><td>LP-2</td><td>0.00</td></tr><tr><td>LP-3</td><td>0.29</td></tr><tr><td>LP-4</td><td>0.53</td></tr><tr><td>LP-5</td><td>0.30</td></tr><tr><td>LP-6</td><td>0.43</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec24"><title>Particle Size of Liqui-Pellet <italic>via</italic> Sieve Method</title><p id="Par37">In Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>, it is clear that all formulations are mostly below 2&#x000a0;mm in size. Formulations LP-1, LP-3, LP-4, and LP-6 are mostly within 1&#x000a0;mm. This shows that it is possible to produce uniform size of liqui-pellet, which is important in regard to quality control in manufacturing for commercial use.<fig id="Fig4"><label>Fig. 4</label><caption><p>Graph showing particle size distribution (PSD) of all formulations <italic>via</italic> sieve method</p></caption><graphic xlink:href="12249_2019_1441_Fig4_HTML" id="MO4"/></fig></p><p id="Par38">Formulations LP-2 and LP-5 have a broader size distribution with smaller size pellets compared to the rest of the liqui-pellet formulations. In regard to formulation LP-2, ~&#x02009;45% and ~&#x02009;35% of total pellet fall within 850&#x000a0;&#x003bc;m and 500&#x000a0;&#x003bc;m respectively. As for formulation LP-5, ~&#x02009;51% and ~&#x02009;5.8% of total pellet fall within 850&#x000a0;&#x003bc;m and 500&#x000a0;&#x003bc;m respectively. This indicates the liquid vehicle can have an effect on liqui-pellet size distribution, which can be assumed to be due to its effect on extrudate plasticity. As for physical mixture pellet, which does not contain liquid vehicle, ~&#x02009;77% of total pellet are within 500&#x000a0;&#x003bc;m. Hence, it seems to indicate liquid vehicle tends to increase pellet size.</p><p id="Par39">Since all of the pellets are almost entirely equal or less than 2&#x000a0;mm, it will be emptied from the stomach into the small intestine relatively fast, similar to how liquid is emptied (<xref ref-type="bibr" rid="CR52">52</xref>). This is advantageous for weakly acidic drugs (<italic>i.e.</italic>, naproxen), as they undergo dissolution at a faster rate in less acidic and more alkaline environment such as the small intestine. Hence, it is suggested that the bioavailability and speed of drug absorption may improve.</p></sec><sec id="Sec25"><title>Stereoscopic Analysis</title><p id="Par40">The Feret&#x02019;s diameter, roundness, and elongation ratio were calculated and shown in Table <xref rid="Tab6" ref-type="table">VI</xref>. In general, the Feret&#x02019;s diameter of the pellet seems to agree with most of the results from particle size analysis. Thus, supporting the claim that different liquid vehicles can influence pellet size and generally increases the pellet size. However, there are some discrepancies between the stereoscopic and particle size analysis. It can be seen that the mean Ferret diameter of the physical mixture pellet, LP-2, and LP-5 could be overestimated. In fact, since the pellets are not perfectly spherical and are usually in the most stable orientation, meaning that the smallest dimension is orientated vertically; therefore, overestimation is likely to occur (<xref ref-type="bibr" rid="CR53">53</xref>). In reality, it is actually difficult to attain perfectly spherical particles.<table-wrap id="Tab6"><label>Table VI</label><caption><p>Stereoscopic Analysis Showing the Mean Feret&#x02019;s Diameter, Mean Roundness, and Mean Elongation of Each Formulation (<italic>n</italic>&#x02009;=&#x02009;100)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Formulations<sup>a</sup></th><th>Mean Feret&#x02019;s diameter (mm)</th><th>Mean roundness &#x000b1; SD<sup>b</sup></th><th>Mean elongation ratio &#x000b1; SD<sup>b</sup></th></tr></thead><tbody><tr><td>Physical mixture pellet</td><td>1.028</td><td>1.25&#x000a0;&#x000b1;&#x000a0;0.12</td><td>1.41&#x000a0;&#x000b1;&#x000a0;0.19</td></tr><tr><td>LP-1</td><td>1.294</td><td>1.12&#x000a0;&#x000b1;&#x000a0;0.07</td><td>1.15&#x000a0;&#x000b1;&#x000a0;0.10</td></tr><tr><td>LP-2</td><td>1.000</td><td>1.12&#x000a0;&#x000b1;&#x000a0;0.03</td><td>1.17&#x000a0;&#x000b1;&#x000a0;0.09</td></tr><tr><td>LP-3</td><td>1.517</td><td>1.14&#x000a0;&#x000b1;&#x000a0;0.09</td><td>1.18&#x000a0;&#x000b1;&#x000a0;0.17</td></tr><tr><td>LP-4</td><td>1.303</td><td>1.18&#x000a0;&#x000b1;&#x000a0;0.07</td><td>1.25&#x000a0;&#x000b1;&#x000a0;0.11</td></tr><tr><td>LP-5</td><td>1.268</td><td>1.24&#x000a0;&#x000b1;&#x000a0;0.11</td><td>1.41&#x000a0;&#x000b1;&#x000a0;0.21</td></tr><tr><td>LP-6</td><td>1.535</td><td>1.38&#x000a0;&#x000b1;&#x000a0;0.18</td><td>1.47&#x000a0;&#x000b1;&#x000a0;0.18</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>For the composition of each formulation, refer to Table <xref rid="Tab1" ref-type="table">I</xref></p><p><sup>b</sup>SD, standard deviation from the mean</p></table-wrap-foot></table-wrap></p><p id="Par41">Formulations LP-6, LP-5, and physical mixture pellet showed the least roundness and largest elongation ratio. Among them, LP-6 has the highest deviation from perfect roundness (1.38) and largest mean elongation ratio (1.47). Nevertheless, the pellets are good enough to achieve excellent flowability (Table <xref rid="Tab3" ref-type="table">III</xref>). As for the rest of the formulations, the results seem to suggest the rest of the liqui-pellets have good roundness and minimal elongation.</p></sec><sec id="Sec26"><title>Morphological Studies on Pellets <italic>via</italic> SEM</title><p id="Par42">According to Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>, it can be seen that physical mixture pellet (PMP) has a rougher surface structure than most of the formulations. This seems to suggest that the co-solvent in liqui-pellet formulations has an influence on the pellet surface morphology, which generally results in a smoother surface. It can be speculated that the dissolved crystals of naproxen in its respective liquid vehicle have contributed to reducing the overall crystallinity of the pellet. Given that all formulations resisted disintegration after the dissolution test, surface morphology after dissolution test was observed. The physical mixture pellet surface structure is not much different from before the dissolution test. As for most of the formulation containing different types of co-solvent, it is observed that their surface structure became rougher after undergoing dissolution test. Since around 49% of the formulated liqui-pellet is liquid medication, it is reasonable to suspect the increase in roughness could be due to liquid medication moving out from the pellet into the dissolution medium, resulting the pellet reverting back to a more crystalline structure or shrinking into a rougher surface structure. Also, there may have been slight disintegration around the surface when the liquid medication leaves the pellet. The fact that it is possible to study the morphology of the pellets after undergoing dissolution test demonstrates the strong bonding within the microcrystalline cellulose structure, rendering the pellet non-disintegrating.<fig id="Fig5"><label>Fig. 5</label><caption><p>Images from SEM of all formulation; <bold>I</bold>. &#x000d7;&#x02009;80 magnification, <bold>II</bold>. &#x000d7;&#x02009;200 magnification, and <bold>III</bold>. &#x000d7;&#x02009;800 magnification. Note <sup>a</sup> refers to pellet before undergoing dissolution test and <sup>b</sup> SD refers to after dissolution test</p></caption><graphic xlink:href="12249_2019_1441_Fig5_HTML" id="MO5"/></fig></p><p id="Par43">When observing liqui-pellet surface structure before the dissolution test (Fig. <xref rid="Fig5" ref-type="fig">5</xref>), it can be observed that different liquid vehicles give a different surface structure. Formulations containing PEG 200 (LP-1) or Tween 80 (LP-3) have similar surface structure and both produce relatively rough surface in comparison to the other liqui-pellet formulations (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). Such surface structure is different from the formulation containing PG (LP-2) or Kolliphor EL (LP-6) where both produce smooth surface liqui-pellet. Liqui-pellet containing Labrafil (LP-4) and Labrasol (LP-5) has a similar surface structure to one another. As shown in Fig. <xref rid="Fig5" ref-type="fig">5</xref>, both of their surface structure are relatively smooth but interestingly have a smooth round bump that resembles micron-size pebbles. It will be interesting to see how these various surface morphologies may have an impact on the success of applying coating techniques in these pellets in future studies.</p><p id="Par44">The results from the morphology studies and dissolution studies show no significant correlation between surface structures affecting the dissolution rate. This could be due to the drug release rate being affected by many additional factors as well as surface properties including drug solubility and physicochemical characteristics of liquid vehicle (<xref ref-type="bibr" rid="CR1">1</xref>). Hence, this may be the reason why it does not appear to be clear how surface structure affects the drug release rate. Further studies on the surface structure are needed on liqui-pellet to determine its impact on drug release.</p></sec><sec id="Sec27"><title>Drug Release Study</title><p id="Par45">The dissolution profiles of all formulations at pH 1.2 are shown in Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>. It should be noted that, although naproxen is poorly soluble in acidic condition and the dissolution test should be carried out at higher pH or with sink condition, for comparison purpose, the dissolution of liqui-pellets was initially carried out at pH 1.2. It can be seen clearly in Figs. <xref rid="Fig6" ref-type="fig">6</xref> and <xref rid="Fig7" ref-type="fig">7</xref> that liquid vehicle causes considerable enhancement of drug release rate compared to physical mixture pellet (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), which does not contain a liquid vehicle. The difference factor (F<sub>1</sub>) and similarity factor (F<sub>2</sub>) of the best formulation (LP-3) and physical mixture at acidic condition are 73.16 and 53.53 respectively. As seen, the F<sub>1</sub> value indicates a marked difference in dissolution profile. The <italic>p</italic> value and F<sub>1</sub> value indicate that there is a difference in dissolution profile. The enhanced drug release <italic>via</italic> API solubilized or held at molecularly dispersed state is maintained even after extrusion and spheronization. This demonstrates that the enhanced drug release mechanism <italic>via</italic> liquisolid concept can be combined with the pelletization technique mentioned earlier.<fig id="Fig6"><label>Fig. 6</label><caption><p>Dissolution profile of pellets in capsule for naproxen 25&#x000a0;mg with various liquid vehicles and physical mixture pellet (pH 1.2)</p></caption><graphic xlink:href="12249_2019_1441_Fig6_HTML" id="MO6"/></fig><fig id="Fig7"><label>Fig. 7</label><caption><p>Dissolution profile of pellets in capsule for naproxen 25&#x000a0;mg with various liquid vehicles and physical mixture pellet (pH 7.4)</p></caption><graphic xlink:href="12249_2019_1441_Fig7_HTML" id="MO7"/></fig></p><p id="Par46">Despite the solubility test (Table <xref rid="Tab2" ref-type="table">II</xref>), the dissolution results at pH 1.2 (Fig. <xref rid="Fig6" ref-type="fig">6</xref>) show formulation with Tween 80 (LP-3) achieving the fastest drug release rate in comparison to the other formulations with different liquid vehicles. Tween 80 has the fastest drug release rate followed by Kolliphor EL (LP-6) then Labrasol (LP-5). Admittedly, even though the formulation with Tween 80 has the fastest dissolution rate, the percentage cumulative drug release is about 17% after 2&#x000a0;h, which is poor. Nonetheless, the poor dissolution rate is expected as naproxen is poorly soluble under acidic pH (37) and the microcrystalline-based pellets are not suitable for fast release formulation due to resistance to disintegration (<xref ref-type="bibr" rid="CR54">54</xref>).</p><p id="Par47">It is obvious that drug release rate increases significantly at pH 7.4 (Fig. <xref rid="Fig7" ref-type="fig">7</xref>); however, what is interesting is that the formulation containing Labrasol (LP-5) has the fastest drug release rate of ~&#x02009;75% after 2&#x000a0;h instead of Tween 80 (LP-3), which is ~&#x02009;66% after 2&#x000a0;h. This shows a different trend compared to the results when the pH is 1.2. Their F<sub>1</sub> and F<sub>2</sub> are 9.23 and 66.04 respectively, indicating little difference in dissolution profile. Also, at pH 7.4, Tween 80 (LP-3) and Kolliphor EL (LP-6) dissolution profile are almost identical (F<sub>1</sub>&#x02009;=&#x02009;1.43 and F<sub>2</sub>&#x02009;=&#x02009;95.66). Furthermore, around 90&#x000a0;min during the dissolution test, Labrafil (LP-4) drug release profile is similar to that of Tween 80 and Kolliphor EL. Such changes in dissolution profile in comparison to the results obtained at pH 1.2 suggest that pH can affect different liquid vehicles&#x02019; influence on drug release rate, and the degree of this effect depends on the choice of liquid vehicle. Thus, the effect of pH on different liquid vehicles seems fundamental for future studies, particularly in choosing the most appropriate co-solvent for a specific region of the gastrointestinal tract which the drug was supposed to be released most efficiently in. In this case, the authors believe that Tween 80 is the most suitable liquid vehicle since the aim is to have a fast onset of action and fast drug release rate. Thus, it is prudent that the drug release rate is high in acidic condition as the drug will be in the stomach before entering the small intestine. It should be noted that although the aim is to have a fast onset of action and fast drug release, in reality, a drug like naproxen would have enteric coat due to potential GI irritation and the main site of absorption will be in the small intestine.</p><p id="Par48">Despite Labrasol having the best drug release at pH 7.4, Tween 80 drug release rate is only ~&#x02009;10% lower than Labrasol. Nonetheless, Labrasol and Kolliphor EL may also be a suitable liquid vehicle for naproxen. In studies by Tiong and Elkordy, liquisolid tablet containing Kolliphor EL (formerly known as cremophor EL) and naproxen of 20% <italic>w</italic>/<italic>w</italic> gave the fastest release, confirming that Kolliphor EL may also be a suitable liquid vehicle for naproxen (<xref ref-type="bibr" rid="CR35">35</xref>).</p></sec><sec id="Sec28"><title>DSC Studies</title><p id="Par49">Thermogram obtained from the DSC includes naproxen, Avicel, Aerosil, Primojel, physical mixture pellets, LP-3, LP-5, and LP-6 (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>). There is a sharp endothermic peak (T<sub>m</sub>&#x02009;=&#x02009;158.77&#x000b0;C and &#x00394;H&#x02009;=&#x02009;92.06&#x000a0;J/g) for naproxen, indicating its crystalline state. Avicel (T<sub>m</sub>&#x02009;=&#x02009;72.67&#x000b0;C and &#x00394;H&#x02009;=&#x02009;94.82&#x000a0;J/g) and Primojel (T<sub>m</sub>&#x02009;=&#x02009;83.82&#x000b0;C and &#x00394;H&#x02009;=&#x02009;167.36&#x000a0;J/g) show broad peaks which could be due to water within Avicel and Primojel evaporating, as they are hygroscopic materials. The evaporation of water is also observed by Tiong and Elkordy (<xref ref-type="bibr" rid="CR48">48</xref>). Aerosil had no definitive peak.<fig id="Fig8"><label>Fig. 8</label><caption><p>DSC traces of Avicel, Aerosil, physical mixture pellet, LP-3, LP-5, and LP-6. Note, the scales of excipients and formulations are different in order to show the peak more clearly</p></caption><graphic xlink:href="12249_2019_1441_Fig8_HTML" id="MO8"/></fig></p><p id="Par50">In the physical mixture pellet trace (Fig. <xref rid="Fig8" ref-type="fig">8</xref>), the peak is at a lower temperature than naproxen (Fig. <xref rid="Fig8" ref-type="fig">8</xref>). The peak shifts from 158.77&#x000b0;C (Fig. <xref rid="Fig8" ref-type="fig">8</xref>) to 149.80&#x000b0;C (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>), which could be due to the Avicel affecting the overall peak of naproxen in the physical mixture pellets. Nevertheless, the crystalline state of naproxen is still present.<fig id="Fig9"><label>Fig. 9</label><caption><p>Diffractograms of naproxen, Avicel, Aerosil, physical mixture pellet, LP-3, LP-5, and LP-6</p></caption><graphic xlink:href="12249_2019_1441_Fig9_HTML" id="MO9"/></fig></p><p id="Par51">However, in formulation LP-3 (T<sub>m</sub>&#x02009;=&#x02009;120&#x000b0;C and &#x00394;H&#x02009;=&#x02009;1.9060&#x000a0;J/g), LP-5 (T<sub>m</sub>&#x02009;=&#x02009;111.98&#x000b0;C and &#x00394;H&#x02009;=&#x02009;2.4048&#x000a0;J/g), and LP-6 (T<sub>m</sub>&#x02009;=&#x02009;121.48&#x000b0;C and &#x00394;H&#x02009;=&#x02009;3.5034&#x000a0;J/g), the DSC traces show the absence of naproxen peak and that T<sub>m</sub> is lower than physical mixture. This indicates that liqui-pellets have reduced crystallinity and possibly have become more amorphous; thus, the improvement in dissolution.</p></sec><sec id="Sec29"><title>XRPD Studies</title><p id="Par52">Naproxen has major peaks at 2&#x003b8; values of 12.2, 16.2, 18.4, 19.6, 22.2, 23.2, 26.8, and 27.8<sup>o</sup> (Fig. <xref rid="Fig9" ref-type="fig">9</xref>). These peaks are similar to the naproxen diffractogram in Maghsoodi studies (<xref ref-type="bibr" rid="CR55">55</xref>). However, the differences are in the presence of a sharp peak at ~&#x02009;7<sup>o</sup> and the absence of peak at 26.8<sup>o</sup> compared to Maghsoodi studies. Naproxen peaks are also similar to naproxen diffractogram in Mello and Ricci-Junior studies (<xref ref-type="bibr" rid="CR56">56</xref>), but again, there are some differences too. This could be due to a different scan rate settings. Nonetheless, the main diagnostic peaks of naproxen are present.</p><p id="Par53">The physical mixture and the chosen formulation (LP-3, LP-5, and LP-6) diffractograms (Fig. <xref rid="Fig9" ref-type="fig">9</xref>) have no peaks other than that of naproxen and Avicel, which indicates no interaction between the excipients and the API. It is clear from Fig. <xref rid="Fig9" ref-type="fig">9</xref> that physical mixture and formulation LP-3, LP-5, and LP-6 have reduced crystallinity compared to the pure naproxen, agreeing with the result observed in the DSC test. The reduced crystallinity partially could be due to the presence of Avicel in the samples particularly in the case of physical mixtures as the drug should be in crystalline state. In the case of liquid-pellet formulation, it could also be due to molecularly dispersion of naproxen. From Fig. <xref rid="Fig9" ref-type="fig">9</xref>, it is difficult to say physical mixture is more crystalline compared to liquid-pellet formulations. This is unusual and unexpected as it was assumed that liqui-pellet would be less crystalline than the physical mixture pellet due to the liquid vehicle dissolving the crystalline API. It is thought that perhaps the amorphous nature of some of the excipients may have overlapped naproxen sharp peaks in the physical mixtures. Also, other factors such as inconsistency in particle size and amount of sample place for XRPD may have influenced the diffraction peak.</p></sec></sec></sec><sec id="Sec30"><title>CONCLUSION</title><p id="Par54">The emerging next-generation oral dosage form, liqui-pellet, has shown remarkable results in terms of overcoming the major drawbacks in liquisolid technology. Liqui-pellet is able to achieve high liquid load factor whilst maintaining excellent flow property, which has never been achieved in liquisolid technology before. Excellent-good flow property was obtained from all liqui-pellet formulations which had liquid load factor of 1. This is one of the key factors for the observed improvement in enhanced drug release. With major drawbacks of liquisolid technology being overcome using liqui-pellet, the liqui-pellet is anticipated as a highly commercially feasible product. Furthermore, there is potential for further optimization as parameters, such as R-value, and choices of excipients may not need to be compromised by flow property.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><p>The authors would like to thank Mr. Daniel Holt for his technical assistance in XRPD.</p></ack><notes><title>Compliance with Ethical Standards</title><notes notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par55">The authors declare that they have no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spireas</surname><given-names>S</given-names></name><name><surname>Sadu</surname><given-names>S</given-names></name></person-group><article-title>Enhancement of prednisolone dissolution properties using liquisolid compacts</article-title><source>Int J Pharm</source><year>1998</year><volume>166</volume><issue>2</issue><fpage>177</fpage><lpage>188</lpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>CA</given-names></name><name><surname>Lombardo</surname><given-names>F</given-names></name><name><surname>Dominy</surname><given-names>BW</given-names></name><name><surname>Feeney</surname><given-names>PJ</given-names></name></person-group><article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title><source>Adv Drug Deliv Rev</source><year>2001</year><volume>46</volume><issue>1&#x02013;3</issue><fpage>3</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">11259830</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Nanocrystals EML. Resolving pharmaceutical formulation issues associated with poorly water soluble compounds. Particles. 2002.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Spireas</surname><given-names>S</given-names></name><name><surname>Bolton</surname><given-names>SM</given-names></name></person-group><source>Liquisolid systems and methods of preparing same. Google Patents</source><year>1998</year></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nokhodchi</surname><given-names>A</given-names></name><name><surname>Hentzschel</surname><given-names>CM</given-names></name><name><surname>Leopold</surname><given-names>CS</given-names></name></person-group><article-title>Drug release from liquisolid systems: speed it up, slow it down</article-title><source>Expert Opin Drug Deliv</source><year>2011</year><volume>8</volume><issue>2</issue><fpage>191</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">21222556</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nokhodchi</surname><given-names>A</given-names></name><name><surname>Aliakbar</surname><given-names>R</given-names></name><name><surname>Desai</surname><given-names>S</given-names></name><name><surname>Javadzadeh</surname><given-names>Y</given-names></name></person-group><article-title>Liquisolid compacts: The effect of cosolvent and HPMC on theophylline release</article-title><source>Colloids Surf B: Biointerfaces</source><year>2010</year><volume>79</volume><issue>1</issue><fpage>262</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">20451361</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javadzadeh</surname><given-names>Yousef</given-names></name><name><surname>Musaalrezaei</surname><given-names>Leila</given-names></name><name><surname>Nokhodchi</surname><given-names>Ali</given-names></name></person-group><article-title>Liquisolid technique as a new approach to sustain propranolol hydrochloride release from tablet matrices</article-title><source>International Journal of Pharmaceutics</source><year>2008</year><volume>362</volume><issue>1-2</issue><fpage>102</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">18647643</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahmy</surname><given-names>RH</given-names></name><name><surname>Kassem</surname><given-names>MA</given-names></name></person-group><article-title>Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation</article-title><source>Eur J Pharm Biopharm</source><year>2008</year><volume>69</volume><issue>3</issue><fpage>993</fpage><lpage>1003</lpage><pub-id pub-id-type="pmid">18396390</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spireas</surname><given-names>S</given-names></name><name><surname>Sadu</surname><given-names>S</given-names></name><name><surname>Grover</surname><given-names>R</given-names></name></person-group><article-title>In vitro evaluation of hydrocortisone liquisolid tablets</article-title><source>J Pharm Sci</source><year>1998</year><volume>87</volume><issue>7</issue><fpage>867</fpage><lpage>872</lpage><pub-id pub-id-type="pmid">9649356</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hancock</surname><given-names>BC</given-names></name></person-group><article-title>Disordered drug delivery: destiny, dynamics and the Deborah number</article-title><source>J Pharm Pharmacol</source><year>2002</year><volume>54</volume><issue>6</issue><fpage>737</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">12078989</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>TL</given-names></name><name><surname>Overhoff</surname><given-names>KA</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Santiago</surname><given-names>P</given-names></name><name><surname>Yacaman</surname><given-names>MJ</given-names></name><name><surname>Johnston</surname><given-names>KP</given-names></name><etal/></person-group><article-title>Micronized powders of a poorly water soluble drug produced by a spray-freezing into liquid-emulsion process</article-title><source>Eur J Pharm Biopharm</source><year>2003</year><volume>55</volume><issue>2</issue><fpage>161</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">12637092</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasenack</surname><given-names>N</given-names></name><name><surname>Hartenhauer</surname><given-names>H</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>BW</given-names></name></person-group><article-title>Microcrystals for dissolution rate enhancement of poorly water-soluble drugs</article-title><source>Int J Pharm</source><year>2003</year><volume>254</volume><issue>2</issue><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">12623189</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ticehurst</surname><given-names>MD</given-names></name><name><surname>Basford</surname><given-names>PA</given-names></name><name><surname>Dallman</surname><given-names>CI</given-names></name><name><surname>Lukas</surname><given-names>TM</given-names></name><name><surname>Marshall</surname><given-names>PV</given-names></name><name><surname>Nichols</surname><given-names>G</given-names></name><etal/></person-group><article-title>Characterisation of the influence of micronisation on the crystallinity and physical stability of revatropate hydrobromide</article-title><source>Int J Pharm</source><year>2000</year><volume>193</volume><issue>2</issue><fpage>247</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">10606789</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kayrak</surname><given-names>D</given-names></name><name><surname>Akman</surname><given-names>U</given-names></name><name><surname>Horta&#x000e7;su</surname><given-names>&#x000d6;</given-names></name></person-group><article-title>Micronization of Ibuprofen by RESS</article-title><source>J Supercrit Fluids</source><year>2003</year><volume>26</volume><issue>1</issue><fpage>17</fpage><lpage>31</lpage></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borba</surname><given-names>Paola Aline Amarante</given-names></name><name><surname>Pinotti</surname><given-names>Marih&#x000e1;</given-names></name><name><surname>de Campos</surname><given-names>Carlos Eduardo Maduro</given-names></name><name><surname>Pezzini</surname><given-names>Bianca Ramos</given-names></name><name><surname>Stulzer</surname><given-names>Hellen Karine</given-names></name></person-group><article-title>Sodium alginate as a potential carrier in solid dispersion formulations to enhance dissolution rate and apparent water solubility of BCS II drugs</article-title><source>Carbohydrate Polymers</source><year>2016</year><volume>137</volume><fpage>350</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">26686139</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>M</given-names></name><name><surname>Okagaki</surname><given-names>T</given-names></name><name><surname>Narisawa</surname><given-names>S</given-names></name><name><surname>Koida</surname><given-names>Y</given-names></name><name><surname>Nakajima</surname><given-names>K</given-names></name></person-group><article-title>Improvement of dissolution characteristics and bioavailability of poorly water-soluble drugs by novel cogrinding method using water-soluble polymer</article-title><source>Int J Pharm</source><year>1998</year><volume>160</volume><issue>1</issue><fpage>11</fpage><lpage>19</lpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barzegar-Jalali</surname><given-names>M</given-names></name><name><surname>Valizadeh</surname><given-names>H</given-names></name><name><surname>Shadbad</surname><given-names>MRS</given-names></name><name><surname>Adibkia</surname><given-names>K</given-names></name><name><surname>Mohammadi</surname><given-names>G</given-names></name><name><surname>Farahani</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cogrinding as an approach to enhance dissolution rate of a poorly water-soluble drug (gliclazide)</article-title><source>Powder Technol</source><year>2010</year><volume>197</volume><issue>3</issue><fpage>150</fpage><lpage>158</lpage></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Application of phospholipid complex technique to improve the dissolution and pharmacokinetic of probucol by solvent-evaporation and co-grinding methods</article-title><source>Int J Pharm</source><year>2014</year><volume>474</volume><issue>1&#x02013;2</issue><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">25108049</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alaei</surname><given-names>S</given-names></name><name><surname>Ghasemian</surname><given-names>E</given-names></name><name><surname>Vatanara</surname><given-names>A</given-names></name></person-group><article-title>Spray drying of cefixime nanosuspension to form stabilized and fast dissolving powder</article-title><source>Powder Technol</source><year>2015</year><volume>288</volume><fpage>241</fpage><lpage>248</lpage></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Lian</surname><given-names>R</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization</article-title><source>Int J Pharm</source><year>2012</year><volume>438</volume><fpage>287</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">22989976</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neslihan Gursoy</surname><given-names>R</given-names></name><name><surname>Benita</surname><given-names>S</given-names></name></person-group><article-title>Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs</article-title><source>Biomed Pharmacother</source><year>2004</year><volume>58</volume><issue>3</issue><fpage>173</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">15082340</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pouton</surname><given-names>CW</given-names></name></person-group><article-title>Formulation of self-emulsifying drug delivery systems</article-title><source>Adv Drug Deliv Rev</source><year>1997</year><volume>25</volume><issue>1</issue><fpage>47</fpage><lpage>58</lpage></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gullapalli</surname><given-names>RP</given-names></name></person-group><article-title>Soft gelatin capsules (softgels)</article-title><source>J Pharm Sci.</source><year>2010</year><volume>99</volume><fpage>4107</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">20737624</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L</given-names></name></person-group><article-title>Amorphous pharmaceutical solids: preparation, characterization and stabilization</article-title><source>Adv Drug Deliv Rev</source><year>2001</year><volume>48</volume><issue>1</issue><fpage>27</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">11325475</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hancock</surname><given-names>BC</given-names></name><name><surname>Parks</surname><given-names>M</given-names></name></person-group><article-title>What is the true solubility advantage for amorphous pharmaceuticals?</article-title><source>Pharm Res</source><year>2000</year><volume>17</volume><issue>4</issue><fpage>397</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">10870982</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duki&#x00107;-Ott</surname><given-names>A</given-names></name><name><surname>Thommes</surname><given-names>M</given-names></name><name><surname>Remon</surname><given-names>JP</given-names></name><name><surname>Kleinebudde</surname><given-names>P</given-names></name><name><surname>Vervaet</surname><given-names>C</given-names></name></person-group><article-title>Production of pellets via extrusion-spheronisation without the incorporation of microcrystalline cellulose: a critical review</article-title><source>Eur J Pharm Biopharm</source><year>2009</year><volume>71</volume><issue>1</issue><fpage>38</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">18771727</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fielden</surname><given-names>KE</given-names></name><name><surname>Newton</surname><given-names>JM</given-names></name><name><surname>Rowe</surname><given-names>RC</given-names></name></person-group><article-title>The influence of moisture content on spheronization of extrudate processed by a ram extruder</article-title><source>Int J Pharm</source><year>1993</year><volume>97</volume><issue>1</issue><fpage>79</fpage><lpage>92</lpage></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>PJ</given-names></name><name><surname>Newton</surname><given-names>JM</given-names></name><name><surname>Rowe</surname><given-names>RC</given-names></name></person-group><article-title>Convergent flow analysis in the extrusion of wet powder masses</article-title><source>J Pharm Pharmacol</source><year>1984</year><volume>36</volume><issue>12</issue><fpage>796</fpage><lpage>798</lpage><pub-id pub-id-type="pmid">6151969</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>PJ</given-names></name><name><surname>Newton</surname><given-names>JM</given-names></name><name><surname>Rowe</surname><given-names>RC</given-names></name></person-group><article-title>Flow defects in wet powder mass extrusion</article-title><source>J Pharm Pharmacol</source><year>1985</year><volume>37</volume><issue>2</issue><fpage>81</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">2858554</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ku</surname><given-names>CC</given-names></name><name><surname>Joshi</surname><given-names>YM</given-names></name><name><surname>Bergum</surname><given-names>JS</given-names></name><name><surname>Jain</surname><given-names>NB</given-names></name></person-group><article-title>Bead manufacture by extrusion/spheronization&#x02014;a statistical design for process optimization</article-title><source>Drug Dev Ind Pharm</source><year>1993</year><volume>19</volume><issue>13</issue><fpage>1505</fpage><lpage>1519</lpage></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>JF</given-names></name><name><surname>Buckton</surname><given-names>G</given-names></name><name><surname>Newton</surname><given-names>JM</given-names></name></person-group><article-title>The influence of four selected processing and formulation factors on the production of spheres by extrusion and spheronisation</article-title><source>Int J Pharm</source><year>1992</year><volume>83</volume><issue>1</issue><fpage>187</fpage><lpage>196</lpage></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>LSC</given-names></name><name><surname>Heng</surname><given-names>PWS</given-names></name><name><surname>Liew</surname><given-names>CV</given-names></name></person-group><article-title>Spheronization conditions on spheroid shape and size</article-title><source>Int J Pharm</source><year>1993</year><volume>96</volume><issue>1</issue><fpage>59</fpage><lpage>65</lpage></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bechgaard</surname><given-names>H</given-names></name><name><surname>Nielsen</surname><given-names>GH</given-names></name></person-group><article-title>Controlled-release multiple-units and single-unit doses a literature review</article-title><source>Drug Dev Ind Pharm</source><year>1978</year><volume>4</volume><issue>1</issue><fpage>53</fpage><lpage>67</lpage></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>AD</given-names></name></person-group><article-title>A new technique for production of spherical particles</article-title><source>Manuf Chem</source><year>1970</year><volume>41</volume><issue>6</issue><fpage>40</fpage></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiong</surname><given-names>N</given-names></name><name><surname>Elkordy</surname><given-names>AA</given-names></name></person-group><article-title>Effects of liquisolid formulations on dissolution of naproxen</article-title><source>Eur J Pharm Biopharm</source><year>2009</year><volume>73</volume><issue>3</issue><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">19679184</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javadzadeh</surname><given-names>Y</given-names></name><name><surname>Jafari-Navimipour</surname><given-names>B</given-names></name><name><surname>Nokhodchi</surname><given-names>A</given-names></name></person-group><article-title>Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine)</article-title><source>Int J Pharm</source><year>2007</year><volume>341</volume><issue>1&#x02013;2</issue><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">17498898</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Sirolimus solid self-microemulsifying pellets: formulation development, characterization and bioavailability evaluation</article-title><source>Int J Pharm</source><year>2012</year><volume>438</volume><issue>1&#x02013;2</issue><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">22850296</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Kaialy W, Martin GP, Ticehurst MD, Royall P, Mohammad MA, Murphy J, <italic>et al</italic>. Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol / butanol for improved drug delivery from dry powder inhalers. 2011;13(1):30&#x02013;43.</mixed-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mora</surname><given-names>CP</given-names></name><name><surname>Martinez</surname><given-names>F</given-names></name></person-group><article-title>Thermodynamic quantities relative to solution processes of Naproxen in aqueous media at pH 1.2 and 7.4</article-title><source>Phys Chem Liq</source><year>2006</year><volume>44</volume><issue>5</issue><fpage>585</fpage><lpage>596</lpage></element-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Diffraction X. Standard test method for determination of relative crystallinity of Zeolite ZSM-5 by. 2012;i(Reapproved 2011):23&#x02013;26.</mixed-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>JW</given-names></name><name><surname>Flanner</surname><given-names>HH</given-names></name></person-group><article-title>Mathematical comparison of dissolution profiles</article-title><source>Pharm Technol</source><year>1996</year><volume>20</volume><issue>6</issue><fpage>64</fpage><lpage>74</lpage></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Hara</surname><given-names>T</given-names></name><name><surname>Dunne</surname><given-names>A</given-names></name><name><surname>Butler</surname><given-names>J</given-names></name><name><surname>Devane</surname><given-names>J</given-names></name></person-group><article-title>A review of methods used to compare dissolution profile data</article-title><source>Pharm Sci Technol Today</source><year>1998</year><volume>1</volume><issue>5</issue><fpage>214</fpage><lpage>223</lpage></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>FDA</collab></person-group><article-title>Guidance for industry dissolution testing of immediate</article-title><source>Evaluation</source><year>1997</year><volume>4</volume><issue>August</issue><fpage>15</fpage><lpage>22</lpage></element-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">FDA. Guidance for industry guidance for industry, chemistry, manufacturing, and controls<italic>:</italic> in vitro dissolution testing and in vivo bioequivalence documentation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluatio. <italic>In Vitro</italic>. 1997;(September).</mixed-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>E</given-names></name><name><surname>De Maesschalck</surname><given-names>R</given-names></name><name><surname>De Spiegeleer</surname><given-names>B</given-names></name><name><surname>Vander Heyden</surname><given-names>Y</given-names></name><name><surname>Smeyers-Verbeke</surname><given-names>J</given-names></name><name><surname>Massart</surname><given-names>DL</given-names></name></person-group><article-title>Evaluation of dissolution profiles using principal component analysis</article-title><source>Int J Pharm</source><year>2001</year><volume>212</volume><issue>1</issue><fpage>41</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">11165819</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>P</given-names></name></person-group><article-title>An alternative method to the evaluation of similarity factor in dissolution testing</article-title><source>Int J Pharm</source><year>2001</year><volume>220</volume><issue>1&#x02013;2</issue><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">11376969</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuksel</surname><given-names>N</given-names></name><name><surname>Kanik</surname><given-names>AE</given-names></name><name><surname>Baykara</surname><given-names>T</given-names></name></person-group><article-title>Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and -independent methods</article-title><source>Int J Pharm</source><year>2000</year><volume>209</volume><issue>1&#x02013;2</issue><fpage>57</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">11084246</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>P</given-names></name><name><surname>Sousa Lobo</surname><given-names>JM</given-names></name></person-group><article-title>Modeling and comparison of dissolution profiles</article-title><source>Eur J Pharm Sci</source><year>2001</year><volume>13</volume><issue>2</issue><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">11297896</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Javaheri H, Carter P, Elkordy AA. Wet granulation to overcome liquisolid technique issues of poor flowability and compactibility: a study to enhance glibenclamide dissolution. J Pharm Drug Deliv. 2014.</mixed-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hentzschel</surname><given-names>CM</given-names></name><name><surname>Sakmann</surname><given-names>A</given-names></name><name><surname>Leopold</surname><given-names>CS</given-names></name></person-group><article-title>Suitability of various excipients as carrier and coating materials for liquisolid compacts</article-title><source>Drug Dev Ind Pharm</source><year>2011</year><volume>37</volume><issue>10</issue><fpage>1200</fpage><lpage>1207</lpage><pub-id pub-id-type="pmid">21449826</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="other">Dastidar DG, Sa B. Research article a comparative study of UV-spectrophotometry and first-order derivative UV-spectrophotometry methods for the estimation of diazepam in presence of Tween-20 and propylene glycol. 2009;10(4):1396&#x02013;1400.</mixed-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>G</given-names></name><name><surname>Newton</surname><given-names>J</given-names></name><name><surname>Short</surname><given-names>M</given-names></name></person-group><article-title>Comparative gastrointestinal transit of pellet systems of varying density</article-title><source>Int J Pharm</source><year>1995</year><volume>114</volume><fpage>1</fpage><lpage>11</lpage></element-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Aulton ME, Taylor KMG. Aulton&#x02019;s pharmaceutics: the design and manufacture of medicines: Elsevier Health Sciences; 2013.</mixed-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamsai</surname><given-names>B</given-names></name><name><surname>Sriamornsak</surname><given-names>P</given-names></name></person-group><article-title>Novel disintegrating microcrystalline cellulose pellets with improved drug dissolution performance</article-title><source>Powder Technol</source><year>2013</year><volume>233</volume><fpage>278</fpage><lpage>285</lpage></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maghsoodi</surname><given-names>M</given-names></name></person-group><article-title>Physicomechanical properties of naproxen-loaded microparticles prepared from Eudragit l100</article-title><source>AAPS Pharm Sci Tech</source><year>2009</year><volume>10</volume><issue>1</issue><fpage>120</fpage><lpage>128</lpage></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Mello</surname><given-names>VA</given-names></name><name><surname>Ricci-J&#x000fa;nior</surname><given-names>E</given-names></name></person-group><article-title>Encapsulation of naproxen in nanostructured system: structural characterization and in vitro release studies</article-title><source>Quim Nova</source><year>2011</year><volume>34</volume><issue>6</issue><fpage>933</fpage><lpage>939</lpage></element-citation></ref></ref-list></back></article>